kb407
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 20, 2021 (NCT05095246)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cystic fibrosis transmembrane conductance regulatorSupplementation
CFTR supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05504837 | Phase 1 | Nov 30, 2022 | Krystal Biotech, Inc. |
| NCT05095246 | Phase 1 | Oct 20, 2021 | Krystal Biotech, Inc., Novotech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Krystal Biotech, Inc. | For profit | 2 | 2 | 1 | 2021 |
| Novotech | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1